Mission Statement

As one of the pioneers in the Ophthalmology space, our mission is to lead the glaucoma market with non-incisional laser therapies that progress the current glaucoma standards and enhance the lives and therapy options for patients globally.

Corporate Overview

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 60 independent distributors into over 100 countries.

The Cyclo G6® Glaucoma Laser allows non-incisional treatment of earlier and late stage glaucoma with IRIDEX-patented MicroPulse® laser mode and continuous wave mode. The 2-3-minute procedure can be performed in an office setting or in the operating room and is an effective alternative to eye drops and invasive surgeries. Over 110,000 patients have been treated with the Cyclo G6 Laser in more than 50 countries since 2015, and it is used in 38 of the 39 best U.S. hospitals for ophthalmology1.

1As ranked by U.S. News and World Report.

Looking for more information on MicroPulse® Laser Technology?

We’re here to answer questions and provide any additional information you may need.